ABU DHABI, UAE — Thrombolytic treatment with recombinant human pro-urokinase was non-inferior to alteplase in achieving an excellent functional outcome in acute ischemic stroke but showed a ...

The effectiveness of alteplase and urokinase in restoring adequate hemodialysis blood-flow rates was examined. A retrospective review of the medical records of hemodialysis patients with central ...

The main flavonol of green tea, epigallocatechin-3-gallate (EGCG), inhibits urokinase 2, one of the hydrolases implicated in tumor invasion. Moreover, green tea consumption by mice significantly ...

Medindia neither buys nor sells drugs. Urokinase (Urolyte) is an enzyme (thrombolytic agent), prescribed for deep vein thrombosis, heart attack, pulmonary embolism and peripheral vascular occlusion.

At the European Association of Nuclear Medicine meeting, Monopar Therapeutics Inc. presented the preclinical characterization of MNPR-101, a first-in-class urokinase-type plasminogen activator ...

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials ...

Monopar’s presentation, accepted as a “Top-Rated Oral Presentation” within the Scientific Program, illustrates the potential of the urokinase plasminogen activator receptor (uPAR ...

More details on this transaction can be found here (link). MNPR-101 for Radiopharmaceutical Use - Phase 1 In August 2024, the Company received regulatory clearance in Australia to commence a ...

Shares of Monopar Therapeutics (NASDAQ:MNPR) shot up 60% in early trading Thursday after the biopharmaceuticals company reported encouraging preclinical data for its MNPR-101 program. The drug ...

The most common clot-busting drugs include Activase (alteplase), Streptase (streptokinase), and Kinlytic (urokinase). Surgery ...

urokinase plasminogen activator surface receptor, and fibroblast growth factor 23), while growth differentiation factor 15 had a stronger relationship with MI in women than in men. "The proteins ...